10
17
5
↑10
↓17
—5
Evidence suggests Iron maydecreaseFatigue.
25 studies (32 claims)
Emerging evidence
Typical effective dose 800 (100–1200) mgacross 5 dosed studies
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| iron replenishment | Increases - improves | symptoms of fatigue | Human | — | Not specified | Effect of postpartum anaemia on maternal health-related quality of life: a systematic review and meta-analysis.cited 27× |
| Iron supplementation in NAID | Increases - associated with improvement | objective scores of fatigue | Human | — | Not specified | Non-anaemic iron deficiency - a disease looking for recognition of diagnosis: a systematic review.cited 95× |
| Iron supplementation in NAID | Increases - associated with improvement | self-rating of fatigue | Human | — | Not specified | Non-anaemic iron deficiency - a disease looking for recognition of diagnosis: a systematic review.cited 95× |
| iron supplementation | Decreases - resolution | fatigue | Human | non-anaemic premenopausal female blood donors with iron deficiency | Not specified | A pilot iron substitution programme in female blood donors with iron deficiency without anaemia.cited 37× |
| iron supplementation | Increases - improved | fatigue | Human | patients with solid tumors and iron deficiency | Not specified | Impact of Iron-Deficiency Management on Quality of Life in Patients with Cancer: A Prospective Cohort Study (CAMARA Study).cited 6× |
| iron supplementation | Decreases - associated with reduced | self-reported fatigue | Human | IDNA adults | All therapy doses, frequencies, and durations were included (not specified). | Efficacy of iron supplementation on fatigue and physical capacity in non-anaemic iron-deficient adults: a systematic review of randomised controlled trials.cited 78× |
| iron supplementation | Decreases - appears to reduce | symptomatic fatigue | Human | women | Not specified for Vitamin A. | Daily iron supplementation for improving anaemia, iron status and health in menstruating women.cited 113× |
| Iron-replacement therapy | Decreases - reduced | fatigue | Human | — | Not specified | Iron Supplementation, Response in Iron-Deficiency Anemia: Analysis of Five Trials.cited 42× |
| intravenous iron therapy | Decreases - will address a substantial knowledge gap in the effects | fatigue | Human | non-dialysis patients with CKD who are iron-deficient but not anaemic | Not specified | The effect of intravenous iron supplementation on exercise capacity in iron-deficient but not anaemic patients with chronic kidney disease: study design and baseline data for a multicentre prospective double-blind randomised controlled trial.cited 4× |
| intravenous iron therapy | Decreases - reduces | symptoms of fatigue | Human | non-dialysis stage 3-4 CKD patients with iron deficiency but without anaemia | Not specified | The effect of intravenous iron supplementation on exercise capacity in iron-deficient but not anaemic patients with chronic kidney disease: study design and baseline data for a multicentre prospective double-blind randomised controlled trial.cited 4× |
| Oral iron supplementation (10 g iron fumarate) | Decreases - significant improvement | fatigue | Human | iron-deficient blood donors | Intravenous iron (1 g ferric carboxymaltose) or oral iron (10 g iron fumarate, 100 capsules). | The Effect of Parenteral or Oral Iron Supplementation on Fatigue, Sleep, Quality of Life and Restless Legs Syndrome in Iron-Deficient Blood Donors: A Secondary Analysis of the IronWoMan RCT.cited 22× |
| Intravenous iron (1 g ferric carboxymaltose) | Decreases - significant improvement | fatigue | Human | iron-deficient blood donors | Intravenous iron (1 g ferric carboxymaltose) or oral iron (10 g iron fumarate, 100 capsules). | The Effect of Parenteral or Oral Iron Supplementation on Fatigue, Sleep, Quality of Life and Restless Legs Syndrome in Iron-Deficient Blood Donors: A Secondary Analysis of the IronWoMan RCT.cited 22× |
| intravenous iron | Decreases - probably results in a slight reduction | fatigue | Human | postpartum women | Not specified for breastfeeding outcomes. | Treatment for women with postpartum iron deficiency anaemia. |
| intravenous iron | Decreases - found statistically significant differences | fatigue and depression scores | Human | women after postpartum haemorrhage without severe anaemia | High single-dose iron infusion (Monofer, iron isomaltoside) | Intravenous iron treatment in the puerperium.cited 6× |
| high single-dose iron infusion | Decreases - found a difference that was statistically significant, but less than the consensus-based and predefined minimal clinically relevant level | aggregated change in physical fatigue | Human | women after postpartum haemorrhage without severe anaemia | High single-dose iron infusion (Monofer, iron isomaltoside) | Intravenous iron treatment in the puerperium.cited 6× |
| intravenous iron supplementation | Increases - has been shown to be a safe, convenient and effective way of improving | exercise tolerance, fatigue and quality-of-life | Human | other patient populations | Repletion and maintenance doses of ferric carboxymaltose (specific amounts not provided). | Rationale and design of the IRON-AF study: a double-blind, randomised, placebo-controlled study to assess the effect of intravenous ferric carboxymaltose in patients with atrial fibrillation and iron deficiency.cited 10× |
| intravenous iron supplementation | No effect - did not reveal any between-group differences | fatigue | Human | non-anemic repeat adult blood donors with iron deficiency (ferritin ≤ 50 µg/L) with pre-specified subgroup analyses of gender, ferritin < 25 µg/L and fatigue ≥ 4 points | Single intravenous dose of 800 mg iron-carboxymaltose. | The effects of intravenous iron supplementation on fatigue and general health in non-anemic blood donors with iron deficiency: a randomized placebo-controlled superiority trial.cited 16× |
| intravenous iron supplementation | No effect - did not reveal any between-group differences | fatigue | Human | non-anemic repeat adult blood donors with iron deficiency (ferritin ≤ 50 µg/L) with exploratory analyses of lower ferritin cut-offs | Single intravenous dose of 800 mg iron-carboxymaltose. | The effects of intravenous iron supplementation on fatigue and general health in non-anemic blood donors with iron deficiency: a randomized placebo-controlled superiority trial.cited 16× |
| intravenous iron supplementation | No effect - had no effect | fatigue | Human | repeat blood donors with low iron stores | Single intravenous dose of 800 mg iron-carboxymaltose. | The effects of intravenous iron supplementation on fatigue and general health in non-anemic blood donors with iron deficiency: a randomized placebo-controlled superiority trial.cited 16× |
| intravenous iron supplementation | No effect - showed no group difference | self-rated mean fatigue scores | Human | non-anemic repeat adult blood donors with iron deficiency (ferritin ≤ 50 µg/L) | Single intravenous dose of 800 mg iron-carboxymaltose. | The effects of intravenous iron supplementation on fatigue and general health in non-anemic blood donors with iron deficiency: a randomized placebo-controlled superiority trial.cited 16× |
| intravenous iron supplementation | Increases - improved perceived fatigue and mood | perceived fatigue and mood | Human | trained athletes with no clinical iron deficiency | Three injections of 2 ml (100 mg) intravenous ferric-carboxymaltose over four weeks (weeks 0, 2, 4). | Four weeks of IV iron supplementation reduces perceived fatigue and mood disturbance in distance runners.cited 25× |
| iron deficiency (ID) | Increases - results in | fatigue | Human | — | Not specified | Dietary Iron and the Elite Dancer.cited 4× |
| iron deficiency | No effect - was not associated with | fatigue | Human | patients undergoing evaluation for colorectal cancer | Not mentioned | The impact of iron deficiency on patients under evaluation for colorectal cancer, a prospective cross-sectional study. |
| iron therapy | Decreases - decreasing | symptoms such as fatigue | Human | women | Not specified | Forty to fifty-five-year-old women and iron deficiency: clinical considerations and quality of life.cited 9× |
| parenteral iron | Increases - improved | maternal fatigue scores | Human | postpartum period | Not specified | The Use of Parenteral Iron Therapy for the Treatment of Postpartum Anemia.cited 10× |
| persistent iron deficiency | No effect - has potential adverse outcomes | fatigue | Human | critically ill patients | Not specified | Iron Metabolism in the Recovery Phase of Critical Illness with a Focus on Sepsis.cited 1× |
| iron supplementations | Increases - The improvement was not solely linked to treatment of anaemia | HRQoL and fatigue | Human | anaemic AUGIB patients | Not specified | Fatigue and acute/chronic anaemia.cited 15× |
| intravenous high single-dose of iron isomaltoside 1000 | No effect - compared to standard medical care on physical fatigue | physical fatigue | Human | women with postpartum haemorrhage | 1,200 mg of iron isomaltoside 1000 (single dose). | Intravenous iron isomaltoside 1000 administered by high single-dose infusions or standard medical care for the treatment of fatigue in women after postpartum haemorrhage: study protocol for a randomised controlled trial.cited 16× |
| intravenous high single dose of iron isomaltoside 1000 | Decreases - superior to standard medical care | physical fatigue | Human | women after postpartum haemorrhage | 1,200 mg of iron isomaltoside 1000 (single dose). | Intravenous iron isomaltoside 1000 administered by high single-dose infusions or standard medical care for the treatment of fatigue in women after postpartum haemorrhage: study protocol for a randomised controlled trial.cited 16× |
| postoperative supplementation with two intravenously administered applications of 200 mg of iron saccharate | Decreases - evaluate the haematopoietic effectiveness | fatigue measured using the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) | Human | adult women undergoing post-bariatric anchor-line abdominoplasty | Intravenous iron saccharate (200 mg, two applications) or oral iron polymaltose (100 mg twice daily). | Postoperative intravenously administered iron sucrose versus postoperative orally administered iron to treat post-bariatric abdominoplasty anaemia (ISAPA): the study protocol for a randomised controlled trial.cited 1× |
| postoperative supplementation with 100 mg of iron polymaltose complex administered orally, twice a day for 8 weeks | Decreases - evaluate the haematopoietic effectiveness | fatigue measured using the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) | Human | adult women undergoing post-bariatric anchor-line abdominoplasty | Intravenous iron saccharate (200 mg, two applications) or oral iron polymaltose (100 mg twice daily). | Postoperative intravenously administered iron sucrose versus postoperative orally administered iron to treat post-bariatric abdominoplasty anaemia (ISAPA): the study protocol for a randomised controlled trial.cited 1× |
| a food-derived dietary supplement containing a low dose of iron and nutrients that increase iron absorption (Blood Builder®/Iron Response®) | Decreases - improved | fatigue | Human | premenopausal women with nonanemic iron deficiency | 26 mg of iron once daily. | A Food-Derived Dietary Supplement Containing a Low Dose of Iron Improved Markers of Iron Status Among Nonanemic Iron-Deficient Women.cited 2× |
| restored iron status | Decreases - resulting in | fewer symptoms such as fatigue | Human | patients after bariatric surgery | Not specified | Iron deficiency before and after bariatric surgery: the need for iron supplementation.cited 12× |
| IV iron | Increases - efficacy | fatigue | Human | patients with fatigue | Not mentioned | The role of iron repletion in adult iron deficiency anemia and other diseases.cited 75× |